Responses
Oncology
Protocol
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Compose a Response to This Article
Other responses
No responses have been published for this article.